Regeneus (ASX:RGS) Announces Collaboration With Kyocera

Regeneus CEO Leo Lee caught up with Finance News Network to talk about the company's collaboration with Japan's Kyocera Corporation to licence, manufacture and commercialise its stem cell therapy treatment Progenza.

Watch Leo's interview via The West Australian here


Regeneus CEO Leo Lee interviewed on ausbiz

Regeneus CEO Leo Lee was interviewed by Australian business, markets, startups news outlet, ausbiz, on Tuesday 11 August following the announcement that Regeneus had signed a new collaboration and licensing agreement with Kyocera for Progenza OA in Japan. In the interview, Leo noted the upfront and milestones payments were worth $27M, and that Regeneus would also receive royalties on product sales.

In the interview, Leo also noted that there were more than 25M potential patients with osteoarthritis in Japan, and that the number of people receiving treatment is rising each year.

Watch Leo's interview here.


Regeneus and Kyocera ink lucrative deal to commercialise Progenza in $3.5 billion dollar market

Financial news outlet finfeed featured Regeneus' Kyocera deal on the day of the announcement, offering in depth analysis of the company, the progress made so far in addressing the global pain market through its differentiated technologies, and the upcoming milestones investors can look forward to.

Read the full article via finfeed here.